SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. , a leading RNAi therapeutics company, announced today that Howard W. Robin, Sirna’s President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw Techvest Healthcare conference on Tuesday, November 8, 2005 at 1:00 p.m. EST (11:00 am MST; 10:00 am PST) at the New York Palace Hotel.
A live audio webcast of the presentation will be available at the Company’s corporate web site at www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. The webcast will also be archived on the Company’s web site for 30 days.
About Sirna Therapeutics
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington’s disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., has been shown to be safe and well tolerated with a trend toward visual acuity improvement and demonstrated biological activity. Sirna has a leading intellectual property portfolio in RNAi with 45 issued patents and over 250 pending applications worldwide. More information on Sirna Therapeutics is available on the Company’s web site at http://www.sirna.com/.
Contacts: Rebecca Galler Robison, Senior Director, Corporate Strategy Sirna Therapeutics, Inc., +1-303-449-6500 Francesca DeMartino (investors) or Jason Rando (media), both of The Ruth Group, +1-646-536-7024 / 7025
Sirna Therapeutics, Inc.
CONTACT: Rebecca Galler Robison, Senior Director, Corporate Strategy ofSirna Therapeutics, Inc., +1-303-449-6500; or Investors, FrancescaDeMartino, +1-646-536-7024, or Media, Jason Rando, +1-646-536-7025, both ofThe Ruth Group, for Sirna Therapeutics, Inc.
Web site: http://www.sirna.com/
